Value of 5-Hydroxymethylcytosine in HBV-Carrying High-Risk Hepatocellular Carcinoma Population: An Evaluation Based on Differential Analysis.
Journal
Computational and mathematical methods in medicine
ISSN: 1748-6718
Titre abrégé: Comput Math Methods Med
Pays: United States
ID NLM: 101277751
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
02
2022
revised:
06
04
2022
accepted:
22
04
2022
entrez:
2
6
2022
pubmed:
3
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
To clarify the application value of 5-hydroxymethylcytosine (5hmC) in evaluating the progression of chronic hepatitis B (CHB) to hepatocellular carcinoma (HCC) based on difference analysis. A total of 180 patients were enrolled. Among them, 84 patients with chronic hepatitis B virus (HBV) infection while no progression to hepatocellular carcinoma (HCC) were included in the control group (CG), and 96 patients with HCC developed from HBV infection were included in the research group (RG). Two-thirds of the samples were used in the training set and 1/3 samples in the validation set to detect the level of 5hmC in both groups based on the modified nano-hmC-Seal technique. The expression levels of 5hmC-related genes TET2 and TET3 were quantified by qPCR, and the correlation between TET3 and 5hmC was analyzed by Pearson's correlation coefficients. Receiver operating characteristic (ROC) curves were drawn to evaluate the application value of the TET3-based 5hmC prediction model in the early diagnosis of HCC. (i) The expression of 5hmC in RG was lower than that in CG, no matter in the training set or the validation set. (ii) 5hmC was significantly enriched in the region between the transcription initiation site and the transcription end site but was depleted in the flanking region. (iii) 5hmC-related genes TET2 and TET3 were significantly downregulated in HCC patients, whether in the training set or the validation set. (iv) In both the training and validation sets, TET3 showed a positive association with 5hmC. (v) ROC analysis results showed that the 5hmC prediction model could be used to predict the progression of CHB to HCC (training set: AUC = 0.81, 0.729-0.893; validation set: AUC = 0.84, 0.739-0.936). TET3 expression based on 5hmC sequencing is a landmark molecule for evaluating the progression of HCC in CHB patients, which is worthy of further study and promotion.
Identifiants
pubmed: 35651922
doi: 10.1155/2022/4835417
pmc: PMC9150989
doi:
Substances chimiques
5-hydroxymethylcytosine
1123-95-1
5-Methylcytosine
6R795CQT4H
Types de publication
Journal Article
Retracted Publication
Langues
eng
Sous-ensembles de citation
IM
Pagination
4835417Commentaires et corrections
Type : RetractionIn
Informations de copyright
Copyright © 2022 Jiao Yu et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Gut. 2019 Dec;68(12):2195-2205
pubmed: 31358576
Clin Epigenetics. 2018 Aug 7;10(1):105
pubmed: 30086793
Hepatology. 2019 Jan;69(1):196-208
pubmed: 30070373
Gastroenterology. 2017 Mar;152(4):812-820.e5
pubmed: 27889576
Cell Rep. 2020 Feb 4;30(5):1310-1318.e5
pubmed: 32023451
Hepatology. 2021 Jan;73 Suppl 1:4-13
pubmed: 32319693
Pathol Oncol Res. 2020 Apr;26(2):599-603
pubmed: 30661224
J Virol. 2021 Feb 24;95(6):
pubmed: 33361417
Cancer Control. 2017 Jul-Sep;24(3):1073274817729245
pubmed: 28975830
Open Virol J. 2018 Feb 28;12:26-32
pubmed: 29541276
Mol Oncol. 2021 Jan;15(1):138-150
pubmed: 33107199
Front Immunol. 2019 Aug 27;10:2048
pubmed: 31507621
Nat Commun. 2020 Oct 19;11(1):5270
pubmed: 33077732
Am J Hum Genet. 2020 Feb 6;106(2):234-245
pubmed: 31928709
Clin Epigenetics. 2015 Sep 11;7:98
pubmed: 26366235
J Gastrointest Oncol. 2017 Apr;8(2):256-265
pubmed: 28480065
Mol Cell Oncol. 2020 Oct 22;7(6):1827904
pubmed: 33235920
PLoS One. 2017 Jan 26;12(1):e0170779
pubmed: 28125731
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):369-73
pubmed: 19967573
Nat Mater. 2017 Nov;16(11):1155-1161
pubmed: 29035356